Ixazomib vs TQB3602

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Proteasome · full Multiple Myeloma pipeline

Ixazomib

Marketed by Takeda Pharmaceutical Company and partners

Approved in Multiple Myelomasmall molecule
Reliable signal

NCT01564537 · Phase 3 · completed

Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).

Next expected readout: March 2027 · NCT04068597 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) (met)

Result source: NCT02312258

TQB3602

Developed by Sino Biopharmaceutical

Phase 1 in Multiple Myelomasmall molecule
Weak signal

NCT04275583 · Phase 1 · status unknown

This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.

Reported efficacy

Dose-limiting toxicity (DLT) (Baseline up to 28 days): Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.

Result source: NCT04275583

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIxazomibTQB3602
PFS, median20.6 vs 14.7+5.9 vs placebon 360NCT01564537
13 other results
—Not reported
OS, median53.6 vs 51.6+2 vs placebon 360NCT01564537
6 other results
—Not reported
ORR78.3% vs 71.5%+6.8 vs placebon 360NCT01564537
10 other results
—Not reported
VGPR or better48.1% vs 39%+9.1 vs placebon 360NCT01564537
2 other results
  • 50% 4 mg + 25 mg + 40 mg · n 32 · Phase 2 · primary NCT02917941
  • 42.2% vs 43.6% n 45 · Phase 4 · secondary NCT03416374
—Not reported
MRD negativity59% vs 50%+9 vs placebowk 72 · n 335NCT01850524
3 other results
—Not reported

PFS, median

Ixazomib
20.6 vs 14.7+5.9 vs placebon 360NCT01564537
13 other results
TQB3602
—Not reported

OS, median

Ixazomib
53.6 vs 51.6+2 vs placebon 360NCT01564537
6 other results
TQB3602
—Not reported

ORR

Ixazomib
78.3% vs 71.5%+6.8 vs placebon 360NCT01564537
10 other results
TQB3602
—Not reported

VGPR or better

Ixazomib
48.1% vs 39%+9.1 vs placebon 360NCT01564537
2 other results
  • 50% 4 mg + 25 mg + 40 mg · n 32 · Phase 2 · primary NCT02917941
  • 42.2% vs 43.6% n 45 · Phase 4 · secondary NCT03416374
TQB3602
—Not reported

MRD negativity

Ixazomib
59% vs 50%+9 vs placebowk 72 · n 335NCT01850524
3 other results
TQB3602
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQB3602
Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better. NCT04275583 · Phase 1 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ixazomib: 4 of 4 rows · TQB3602: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIxazomib
Dropout rate
28.1%a
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
49.3%Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
18.5%
NCT02181413 · Phase 3
n/a: no completion milestone
NCT02312258 · Phase 3
—
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
0%
NCT03748953 · Phase 3 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
3%Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
2.8%Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
10.8%Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneIxazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneIxazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
30%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
22.7%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
0%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
0%Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
0%Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
0%Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
14.3%
NCT02440464 · Phase 2 · registry result, not featured evidence
70.6%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
33.3%4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
88.9%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
89.7%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
82.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
95%
NCT02499081 · Phase 2 · registry result, not featured evidence
0%4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
0%3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
0%90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
25%80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
25%70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
—Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT02181413 · Phase 3
—
NCT02312258 · Phase 3
—
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
—
NCT03748953 · Phase 3 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
—Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Ixazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
13%Ixazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
15%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
4.5%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
—
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
—Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
—Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
—Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
—4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
—
NCT02440464 · Phase 2 · registry result, not featured evidence
32.4%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
—4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
—3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
—2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
22.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
21.8%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
29.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
—
NCT02499081 · Phase 2 · registry result, not featured evidence
—4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
56.8%a
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
—Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
65.4%Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
73%Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
27.4%
NCT02181413 · Phase 3
23.7%
NCT02312258 · Phase 3
37.8%
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
31.4%
NCT03748953 · Phase 3 · registry result, not featured evidence
13.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
48.5%Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
31.4%Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
31.4%Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
38.9%Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
58.3%Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
44.4%Ixazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
52.2%Ixazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
25%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
8.3%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
74.1%Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
45.5%Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
47.6%Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
55.6%4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
52.4%
NCT02440464 · Phase 2 · registry result, not featured evidence
35.3%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
66.7%4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
0%2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
47.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
38.5%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
58.8%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
40%
NCT02499081 · Phase 2 · registry result, not featured evidence
44%4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
57.1%3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
0%90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
42.1%80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
66.7%70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
diarrhoea 51.5% (placebo 42.6%)
constipation 34.6% (placebo 27.6%)
anaemia 34.1% (placebo 29.2%)
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 32 more results
diarrhoea 77% (placebo 30%)
oedema peripheral 55.5% (placebo 32.5%)
constipation 48.2% (placebo 38.1%)
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
diarrhoea 41.7% (placebo 30%)
oedema peripheral 40.5% (placebo 32.5%)
constipation 36.2% (placebo 38.1%)
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
nausea 39.1% (placebo 15.4%)
diarrhoea 34.3% (placebo 23.6%)
arthralgia 26.6% (placebo 16.6%)
NCT02181413 · Phase 3
nausea 27.9% (placebo 8.3%)
diarrhoea 23.9% (placebo 12.7%)
vomiting 23.9% (placebo 4%)
NCT02312258 · Phase 3
diarrhoea 28.9%
white blood cell count decreased 24.4%
platelet count decreased 20%
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 40% (placebo 25%)
diarrhoea 34.3% (placebo 25%)
vomiting 25.7% (placebo 0%)
NCT03748953 · Phase 3 · registry result, not featured evidence
lymphocyte decreased 36.7%
lymphocyte decreased 33.3%
wbc decreased 33.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
fatigue 87.9%
nausea 84.8%
platelet count decreased 81.8%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.3%
peripheral sensory neuropathy 88.6%
platelet count decreased 74.3%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 82.9%
platelet count decreased 80%
peripheral sensory neuropathy 77.1%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.4%
diarrhea 80.6%
nausea 77.8%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
anemia 91.7%
fatigue 91.7%
lymphocyte count decreased 91.7%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
anaemia 33.3%
upper respiratory tract infection 33.3%
aspartate aminotransferase increased 22.2%
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
hypertension 17.4%
upper respiratory tract infection 13%
ankle fracture 8.7%
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
diarrhea 95%
fatigue 50%
nausea 50%
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
diarrhea 50%
fatigue 40.9%
upper respiratory infection 27.3%
NCT02389517 · Phase 2 · registry result, not featured evidence
platelet count decreased 91.7%
lymphocyte count decreased 83.3%
rash 83.3%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
pneumonia 33.3%
colitis 22.2%
upper respiratory infection 22.2%
NCT02765854 · Phase 2 · registry result, not featured evidence
conjunctivits 36.4%
bone pain 18.2%
pneumonia 18.2%
NCT02765854 · Phase 2 · registry result, not featured evidence
thrombocytopenia 42.9%
neutropenia 19%
pneumonia 19%
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
4 mg
diarrhoea 38.9%
peripheral sensory neuropathy 26.4%
fatigue 23.6%
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
pyrexia 14.3% (placebo 4.5%)
myalgia 4.8% (placebo 0%)
upper respiratory tract infection 4.8% (placebo 0%)
NCT02440464 · Phase 2 · registry result, not featured evidence
4 mg + 25 mg + 40 mg
constipation 50%
upper respiratory tract infection 47.1%
diarrhoea 41.2%
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
4 mg
thrombocytopenia 100%
anaemia 66.7%
aspartate aminotransferase increased 66.7%
NCT02168101 · Phase 2 · registry result, not featured evidence
3 mg
gastritis 66.7%
thrombocytopenia 66.7%
abdominal pain 33.3%
NCT02168101 · Phase 2 · registry result, not featured evidence
2.3 mg
diarrhoea 100%
dry eye 66.7%
hypertension 66.7%
NCT02168101 · Phase 2 · registry result, not featured evidence
anaemia 30.6%
diarrhoea 30.6%
upper respiratory tract infection 25%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 33.3%
upper respiratory tract infection 26.9%
anaemia 24.4%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
neutropenia 47.1%
anaemia 32.4%
nausea 29.4%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 85%
hypoalbuminemia 80%
fatigue 75%
NCT02499081 · Phase 2 · registry result, not featured evidence
4 mg
anemia 76%
platelet count decreased 76%
neutrophil count decreased 68%
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
3 mg
anemia 85.7%
lymphocyte count decreased 85.7%
white blood cell decreased 85.7%
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 36 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ixazomib

PFS 7.1 vs 4.8 Pomalidomide months4 mg
time to event · months
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
20.6 vs 14.7 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
18.7 vs 9.3 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
35.3 vs 21.8 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
26.5 vs 21.3 placebo months
NCT02181413 · Phase 3
17.4 vs 9.4 placebo months
NCT02312258 · Phase 3
10.1 vs 9.6 placebo months
NCT02312258 · Phase 3
28.96 vs NA Bortezomib + Lenalidomide + Dexamethasone months
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
Overall Survival 18.8 vs NA Pomalidomide months4 mg
time to event · months
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
show 8 more results
53.6 vs 51.6 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
42.2 vs 29.4 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
46.9 vs 30.9 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
NA vs NA placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
NA vs NA placebo months
NCT02181413 · Phase 3
64.8 vs 69.5 placebo months
NCT02312258 · Phase 3
37.3 vs 48.3 placebo months
NCT02312258 · Phase 3
NA vs NA Bortezomib + Lenalidomide + Dexamethasone months
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
ORR 38% (n=73) vs 41% (n=49) Pomalidomide4 mg
responder rate · % of participants
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
78.3% (n=360) vs 71.5% (n=362) placebo
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
82% (n=351) vs 80% (n=354) placebo
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
73.3% (n=45) vs 83.3% (n=6) Bortezomib + Lenalidomide + Dexamethasone
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
VGPR or Better 48.1% (n=360) vs 39% (n=362) placebo
responder rate · % of participants
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
42.2% (n=45) vs 33.3% (n=6) Bortezomib + Lenalidomide + Dexamethasone
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
Duration of Response 14.8 vs 14.3 Pomalidomide months4 mg
time to event · months
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
26 vs 21.7 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
50.6 vs 37.5 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
28.03 vs 15.31 Bortezomib + Lenalidomide + Dexamethasone months
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
Time to Progression 8.4 vs 5.1 Pomalidomide months4 mg
time to event · months
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
22.4 vs 17.6 placebo months
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
45.8 vs 26.8 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
26.6 vs 21.4 placebo months
NCT02181413 · Phase 3
17.8 vs 9.6 placebo months
NCT02312258 · Phase 3
Complete 26% (n=351) vs 14% (n=354) placebo
responder rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
Pain 50.5% (n=190) vs 51.3% (n=195) placebo
responder rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Response 2 vs 1.1 Pomalidomide months4 mg
time to event · months
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
1.02 vs 1.87 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
MRD Negative 59% (n=335) vs 50% (n=347) placebo @ 72wk
responder rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
6% (n=169) vs 3% (n=125) placebo
NCT02312258 · Phase 3
Skeletal-related 10% (n=163) vs 14% (n=160) placebo
event rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
25% (n=191) vs 14% (n=160) placebo
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR 40% (n=395) vs 45% (n=261) placebo
responder rate · % of participants
VGPR
NCT02181413 · Phase 3
show 1 more result
34% (n=425) vs 37% (n=281) placebo
VGPR
NCT02312258 · Phase 3

+ 150 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ixazomib's landscape · TQB3602's landscape